Structure Therapeutics Inc.
Structure Therapeutics Inc. (GPCR): 143 pipeline candidates · 12 upcoming catalysts · ~47 mo cash runway · 21 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
47.4 months
D/E 0.04 · 2% dilution
Lead: Phase 2
143 candidates
12 upcoming, next in ~196d
0 buys · 10 sells (180d)
A transparent, data-derived signal for Structure Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.2B
Cash
$316.2M
Quarterly Burn
$89.4M
Runway
47.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (143 candidates)
| Drug | Phase |
|---|---|
| ACCG-2671 | Phase 1 |
| accg-3535 | Preclinical |
| Acetaminophen | Phase 4 |
| Acetaminophen 1000 mg/d | N/A |
| Acetaminophen 325Mg Tab | Phase 4 |
| Acetaminophen 4000 mg/d | N/A |
| Acetaminophen 500Mg Tab | Phase 4 |
| Acetylcysteine | Phase 2 |
| Adalimumab | Phase 1 |
| aleniglipron | Phase 2 |
Showing 10 of 143 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
197
Total value held
$2.88B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,403,449 | $405.0M |
| wellington management group llp | 7,260,287 | $349.9M |
| janus henderson group plc | 5,505,798 | $265.5M |
| deep track capital, lp | 4,279,848 | $206.3M |
| bvf inc/il | 3,459,358 | $166.7M |
| morgan stanley | 2,305,457 | $111.1M |
| principal financial group inc | 1,753,764 | $84.5M |
| driehaus capital management llc | 1,577,356 | $76.0M |
| orbimed advisors llc | 1,475,403 | $71.1M |
| american century companies inc | 1,438,031 | $69.3M |
Showing top 10 of 197 institutional holders of Structure Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Structure Therapeutics Inc.'s pipeline?
Structure Therapeutics Inc. (GPCR) has 143 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Structure Therapeutics Inc.'s lead drug candidate?
Structure Therapeutics Inc.'s most advanced tracked candidate is ACCG-2671 (Phase 1) for obesity.
What is Structure Therapeutics Inc.'s next catalyst?
Structure Therapeutics Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: aleniglipron" — expected December 31, 2026.
What is Structure Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Structure Therapeutics Inc. has approximately 47.4 months of cash runway.
What is Structure Therapeutics Inc.'s market capitalization?
Structure Therapeutics Inc.'s market capitalization is approximately $3.2B.
Get the full picture on Structure Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.